Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

[1]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Eberlein.  Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study , 2011 .

[3]  M. Dowsett,et al.  Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response , 2010 .

[4]  C. Perou,et al.  Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Dowsett,et al.  A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer , 2009, Breast Cancer Research and Treatment.

[7]  P. Buchan,et al.  Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone , 2009, Breast Cancer Research and Treatment.

[8]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[9]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[10]  M. Dowsett,et al.  Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study , 2007, British Journal of Cancer.

[11]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[12]  R. Gelber,et al.  Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. , 2006, Journal of the National Cancer Institute.

[13]  M. Vasei,et al.  Status of estrogen and progesterone receptors in various phases of the menstrual cycle in breast cancer. , 2006, Archives of Iranian medicine.

[14]  Frank A. Quinn,et al.  Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer , 2006, Clinical chemistry and laboratory medicine.

[15]  N. Gonchoroff,et al.  Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers , 1997, Annals of Surgical Oncology.

[16]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  D. Coradini,et al.  Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients. , 2003, Annals of Oncology.

[19]  C. Atalay,et al.  Menstrual cycle and hormone receptor status in breast cancer patients. , 2002, Neoplasma (Bratislava).

[20]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[21]  A. Luini,et al.  Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments. , 2001, Critical reviews in oncology/hematology.

[22]  J. Bringer,et al.  A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma , 2001, Cancer.

[23]  J. Klijn,et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. , 2000, Journal of the National Cancer Institute.

[24]  A. Paradiso,et al.  Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome. , 1998, Journal of experimental & clinical cancer research : CR.

[25]  J. Daurès,et al.  Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause , 1998, Cancer.

[26]  F. O'Malley,et al.  Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases , 1998, The Lancet.

[27]  C. Cheng,et al.  Sex hormone-binding globulin changes during the menstrual cycle. , 1985, The Journal of clinical endocrinology and metabolism.

[28]  M. Dowsett,et al.  OESTROGEN‐RELATED CHANGES IN SEX HORMONE BINDING GLOBULIN LEVELS DURING NORMAL AND GONADOTROPHIN‐STIMULATED MENSTRUAL CYCLES , 1985, Clinical endocrinology.

[29]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.